Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.436 USD | +2.06% | +6.37% | -12.30% |
30/04 | Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product | CI |
30/04 | Akili, Inc. to Reduce Workforce | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-12.30% | 3.36Cr | |
+11.18% | 23TCr | |
+9.06% | 19TCr | |
+13.25% | 14TCr | |
+25.98% | 11TCr | |
+0.34% | 6.32TCr | |
+11.58% | 5.23TCr | |
+5.62% | 5.1TCr | |
+6.21% | 4.39TCr | |
+4.92% | 3.81TCr |
- Stock Market
- Equities
- AKLI Stock
- News Akili, Inc.
- Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M